Abstract
The most common forms of fertility treatments provided within cross‐border reproductive care (CBRC) are assisted reproductive technologies, namely in‐vitro fertilization and ICSI, for many indications. The main reasons for CBRC are legal restrictions, high costs and lack of availability of high‐quality treatment in home countries. Due to its complex nature and implications worldwide, CBRC has become an emerging dilemma on the global healthcare agenda and yet little is known about its magnitude and scope. There are huge differences in the medical, legal, economic, and cultural conditions leading to CBRC. As an industry, CBRC involves many different parties, including patients, doctors, brokers, as well as donors and surrogates. Sex selection for nonmedical reasons is an ongoing ethical debate in many societies worldwide, including the US. Standardization of data collection and establishment of reliable national and global registries are still needed in order to determine the accurate magnitude and scope of CBRC worldwide.